Fetzima generic?

When will Fetzima go generic?

Fetzima (levomilnacipran) is a medication used to treat major depressive disorder. Despite its popularity, Fetzima is not yet available in generic form. According to DrugPatentWatch.com, the patent for levomilnacipran, the active ingredient in Fetzima, is set to expire in 2030 [1]. This means that generic versions of the drug will only become available after the patent expires.

Who makes the generic?

The expiration of the patent will allow other companies to manufacture and market generic versions of Fetzima. Several companies, such as Teva Pharmaceuticals and Sandoz, have already indicated their interest in developing generic levomilnacipran [2].

What is the difference between Fetzima and its generic?

Generic medications, including Fetzima, are expected to be cheaper than the brand-name version. However, the generic medication must meet the same quality and safety standards as the brand-name version. This means that generic generic Fetzima will contain the same active ingredient and have the same mechanism of action as Fetzima [3].

Potential side effects and risks

Generic or brand-name, patients taking Fetzima should be aware of the potential side effects, which include dizziness, headaches, and increased blood pressure [4]. Patients should discuss any concerns or questions about taking Fetzima or its generic with their doctor.

References:

[1] DrugPatentWatch.com. (n.d.). Levomilnacipran. Retrieved from https://www.drugpatentwatch.com/US-812-7293A

[2] Generic Business. (2020, October 15). Teva to Launch Generic of Fetzima. Retrieved from https://www.genericbusiness.com/teva-to-launch-generic-fetzima/

[3] FDA.gov. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/questions-answers/generic-drugs

[4] WebMD. (n.d.). Fetzima. Retrieved from https://www.webmd.com/drugs/2/drug-154444/fetzima-oral/details